Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update

Lucid Diagnostics Inc. (NASDAQ:LUCD) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 1,790,000 shares, an increase of 72.1% from the February 13th total of 1,040,000 shares. Currently, 5.6% of the company’s stock are sold short. Based on an average daily volume of 576,100 shares, the short-interest ratio is presently 3.1 days.

Hedge Funds Weigh In On Lucid Diagnostics

Several large investors have recently bought and sold shares of the stock. LPL Financial LLC raised its stake in shares of Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after purchasing an additional 12,035 shares during the period. Sunbelt Securities Inc. bought a new stake in shares of Lucid Diagnostics during the 4th quarter worth $67,000. Citadel Advisors LLC bought a new stake in shares of Lucid Diagnostics during the 4th quarter worth $98,000. Lido Advisors LLC raised its stake in shares of Lucid Diagnostics by 40.0% during the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after purchasing an additional 40,000 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Lucid Diagnostics by 30.9% during the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after purchasing an additional 65,964 shares during the period. 74.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets dropped their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a research note on Monday, December 9th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $3.63.

Lucid Diagnostics Trading Up 8.6 %

Shares of NASDAQ:LUCD opened at $1.39 on Monday. The stock’s fifty day simple moving average is $1.14 and its two-hundred day simple moving average is $0.96. Lucid Diagnostics has a 1-year low of $0.63 and a 1-year high of $1.63. The stock has a market cap of $82.49 million, a PE ratio of -1.22 and a beta of 1.34.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.